Skip to content
KStart free
AI InfrastructureDefenseQuantumAll studies →

COLL US Equity

Collegium Pharmaceutical, IncHealth Care · Pharmaceutical Preparations · CIK 1267565 · FY ends Dec 31
$28.50
+0.43 (+1.53%)
USD · as of 2026-08-18 · marketstack
1 registered study · 0 active

Studies where COLL is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.

1 interventional · 1 with posted results

Held by 12 tracked-famous managers (RENAISSANCE TECHNOLOGIES LLC, MILLENNIUM MANAGEMENT LLC, Qube Research & Technologies Ltd, D. E. Shaw & Co., Inc., MARSHALL WACE, LLP, +7 more) · FINRA short interest 17.4 days to cover (settled 2026-07-31) · government filings 180d: 0 congress / 2 executive

StudyPhaseStatusInterventionsConditionsEnrollmentPrimary completionUpdated
Oxycodone DETERx™ Versus Placebo in Chronic Low Back Pain (CLBP)NCT01685684results2017-02-23Change in Average Pain Intensity Measured by the Change in Pain Intensity-Numeric Rating Scale (PI-NRS) Scores From Randomization Baseline to Week 12 of the Double-blind Maintenance PhaseRandomized · Double-masked · TreatmentPhase 3CompletedDrug: Oxycodone DETERx, PlaceboChronic Low Back Pain740Jun 2014actual2020-10-19

Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.

Source: ClinicalTrials.gov, retrieved 2026-08-19